Universe Pharmaceuticals Gets Nasdaq Delisting Warning
Ticker: UPC · Form: 6-K · Filed: Feb 25, 2025 · CIK: 1809616
| Field | Detail |
|---|---|
| Company | Universe Pharmaceuticals INC (UPC) |
| Form Type | 6-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting-warning, sec-filing, regulatory-news
TL;DR
Nasdaq is warning Universe Pharmaceuticals about delisting due to a delayed annual report.
AI Summary
Universe Pharmaceuticals INC filed a Form 6-K on February 25, 2025, reporting a staff determination notice from Nasdaq concerning its delayed annual report. The company is a foreign private issuer and is subject to Nasdaq's listing rules. The filing includes a press release as an exhibit detailing this notice.
Why It Matters
This Nasdaq notice indicates potential delisting, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A Nasdaq delisting warning poses a significant risk to the company's stock trading and investor perception.
Key Players & Entities
- Universe Pharmaceuticals INC (company) — Filer of the report
- Nasdaq (company) — Exchange where the company is listed and issued a notice
- February 2025 (date) — Reporting period for the Form 6-K
- 20250225 (date) — Filing date of the report
FAQ
What is the primary reason for the Nasdaq staff determination notice received by Universe Pharmaceuticals INC?
Universe Pharmaceuticals INC received the notice from Nasdaq related to its delayed annual report.
What form did Universe Pharmaceuticals INC file on February 25, 2025?
Universe Pharmaceuticals INC filed a Form 6-K.
What is the company's principal executive office address?
The company's principal executive office is located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China, 343100.
Is Universe Pharmaceuticals INC required to file annual reports under Form 20-F or Form 40-F?
Universe Pharmaceuticals INC indicated it files annual reports under Form 20-F.
What exhibit is included with this Form 6-K filing?
Exhibit 99.1, a Press Release titled 'Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report', is included.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 25, 2025 regarding Universe Pharmaceuticals INC (UPC).